TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

Sonalleve, Profound’s second product which is currently offered primarily as a one-time capital sale, is gaining increasing commercial interest, particularly outside of the United States. Sonalleve ...

Mar 27, 2026, 7:45 AM ETProfound Medical Corp. (PROF), PRN:CA The TULSA Procedure, performed using the TULSA-PRO ® system, represents a major advancement in prostate care, and is used by physicians to ...